RoslinCT and BlueRock Therapeutics Partner to Expand Access to Clinical-Grade Pluripotent Cell Lines for Cell Therapy Developers
RoslinCT, a leading global cell therapy Contract Development and Manufacturing Organization, today announced a strategic partnership with BlueRock Therapeutics, a leader in stem cell therapeutic development, to broaden access to clinical-grade pluripotent stem cell lines for cell therapy developers.
Through the partnership, RoslinCT will augment its existing pluripotent cell therapy offering to include access to BlueRock’s clinical-grade induced pluripotent stem cell lines, alongside RoslinCT’s own cell lines and related services. This expanded offering will provide developers with a more comprehensive set of tools and support to accelerate their pluripotent cell-based therapies from early development toward the clinic and commercial manufacture.
Under the agreement, RoslinCT will enable access to matched research-grade samples of BlueRock’s cell lines for prospective customers, while BlueRock will maintain oversight of commercial licensing. RoslinCT and BlueRock have also completed a technical transfer of the cell lines to RoslinCT’s facilities and team, enabling RoslinCT to support customers with services including cell banking, process and analytical development, and the manufacture of drug products for clinical and commercial use.
